Enzalutamide and the more efficient AR antagonist apalutamide appear to be good candidates to limit SARS-CoV-2 infection and should be tested with local treatment in the prostate cancer population vulnerable to severe COVID-19. The gene discussed is AR; the disease is prostate cancer.